Compare BNTC & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTC | PALI |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.4M | 338.9M |
| IPO Year | 2020 | 2019 |
| Metric | BNTC | PALI |
|---|---|---|
| Price | $11.40 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $27.67 | $11.29 |
| AVG Volume (30 Days) | 79.6K | ★ 3.2M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 80.94 | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $9.85 | $0.55 |
| 52 Week High | $17.15 | $2.86 |
| Indicator | BNTC | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 50.98 |
| Support Level | $9.91 | $1.57 |
| Resistance Level | $13.40 | $2.18 |
| Average True Range (ATR) | 0.68 | 0.13 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 38.12 | 48.35 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.